Witryna2 dni temu · Invasive fungal infection (IFI) in immunocompromised neonates is significantly associated with high morbidity and mortality and has become the third most common infection in Neonatal Intensive Care Units. The early diagnosis of IFI for neonatal patients is difficult because of the lack of specific symptoms. The traditional … Witryna6 mar 2024 · Signcryption requires less computational complexity, communication cost, and implementation effort. Moving ahead, Deng and Boa [ 4] suggested a scheme to reduce computational cost by up to 16% and communication cost by up to 85% when compared to the signature-then-encryption technique.
An improved semantically-secure identity-based signcryption …
WitrynaSci-Hub An Improved ID-Based Multi-Proxy Multi-Signcryption Scheme. 2009 Second International Symposium on Electronic Commerce and Security 10.1109/isecs.2009.177 sci hub to open science ↓ save Xiaoyan, Z., Yan, W., Weifeng, D., & Yan, G. (2009). WitrynaImproved Identity-Based Signcryption Abstract. Identity-based cryptography is form of public-key cryptography that does not require users to pre-compute key... Author information. Editor information. Rights and permissions. Copyright information. About … novartis switzerland news
An improved semantically-secure identity-based signcryption …
Witryna11 kwi 2024 · Transformer-based large language models are rapidly advancing in the field of machine learning research, with applications spanning natural language, biology, chemistry, and computer programming. Extreme scaling and reinforcement learning from human feedback have significantly improved the quality of generated text, enabling … WitrynaThe idea of signcryption is to provide a method to encrypt and sign data together in a way that is more e cient than using an encryption scheme combined with a signature … Witryna1 maj 2015 · In this paper, we propose a new privacy-enhancing group signcryption scheme that provides: unforgeability, confidentiality, ciphertext and sender anonymity, traceability, unlinkability,... novartis switzerland basel